Concerns & Risks -- 6/10
A score of 6 reflects a business with genuine, identifiable catalysts (HDF rollout, FME25+
savings, treatment growth normalization) offset by material near-term earnings headwinds
(TDAPA phase-out, ACA subsidy risk, flat U.S. volumes) and a longer-tail existential question
around GLP-1s. The stock trades cheaply, but the cheap multiple is partially justified by
these uncertainties. Upside catalysts are real but back-end loaded (2027+), while risks are
front-loaded in 2026.
Weight: 15%
Forward P/E
9.3x
30%+ discount to DaVita (~12x)
EV/EBITDA
~5.5x
vs. DaVita ~7.4x
Dividend Yield
2.5%
+ EUR 1B buyback program
Price / Market Cap
$22.41 / $12.1B
ADR-listed, EUR reporting
Peer valuation comparison
| Company | Mkt Cap | Trailing P/E | Fwd P/E | EV/EBITDA | EV/Revenue | Div Yield |
|---|---|---|---|---|---|---|
| Fresenius Medical (FMS) | $12.1B | 10.5x | 9.3x | ~5.5x | ~0.8x | 2.5% |
| DaVita (DVA) | ~$13B | ~15.5x | ~12.0x | ~7.4x | ~1.6x | 0% |
| Baxter (BAX) | ~$18B | ~9.0x | ~11x | ~16x | ~1.7x | ~3% |
| Key Takeaway | Meaningful discount to DaVita on every multiple | |||||
FMS trades at a meaningful discount to DaVita on every multiple. The gap reflects (a) European
domicile / ADR discount, (b) lower historic margins, (c) TDAPA-inflated 2025 base creating tough
comps, and (d) currency translation noise (EUR reporting, USD-denominated ADR). At 9.3x forward
earnings with a 2.5% yield and a share buyback in progress, valuation provides a reasonable margin
of safety -- but the discount is not irrational given the headwinds below.
Financial trajectory (EUR)
| Metric | FY2023 | FY2024 | FY2025 | Trend |
|---|---|---|---|---|
| Revenue | EUR 19.5B | EUR 19.3B | EUR 19.6B | Flat (organic +8% masked by divestitures/FX) |
| Operating Income | EUR 1.37B | EUR 1.39B | EUR 1.83B | +27% YoY in 2025 |
| OI ex-Special Items | -- | -- | EUR 2.21B | Strong underlying |
| Net Income (attr.) | EUR 499M | EUR 538M | EUR 978M | +82% YoY |
| OI Margin | 7.0% | 7.2% | 9.3% | 210bps expansion |
| OI Margin ex-SI | -- | -- | 11.3% | Within 2025 target band |
| EBITDA | -- | -- | EUR 3.33B | 17% margin |
| U.S. Patients | 205,308 | 206,436 | 205,483 | Slight decline |
| U.S. Treatments | 31.2M | 31.2M | 31.1M | Flat to slightly down |
Revenue has been flat at ~EUR 19.3-19.6B as organic growth (+8%) is masked by divestitures and FX.
The real story is margin expansion: OI margin expanded 210bps to 9.3% (11.3% ex-special items) driven
by FME25+ cost savings. Net income nearly doubled to EUR 978M. However, U.S. patient counts and
treatments are flat-to-declining -- a key concern for the growth thesis. Data sourced from Daloopa.
Key catalysts (bull case)
| # | Catalyst | Detail | Timeline | Impact |
|---|---|---|---|---|
| 1 | 5008X / HDF Rollout in U.S. | Replacing ~20% of installed base in 2026 (~36,000 patients, 28 states). CONVINCE trial showed 23% mortality reduction after 3 months on HDF. Reduced mortality = more treatments = volume tailwind. Competitive moat vs. DaVita. Full benefit back-loaded (2027+). | 2026-2028 | HIGH |
| 2 | FME25+ Savings Acceleration | EUR 250M incremental savings targeted in 2026; total EUR 1.2B by end-2027. Already exceeded prior targets (EUR 804M achieved vs. EUR 500M original). Includes ~100 U.S. clinic closures for footprint rationalization. | 2026-2027 | HIGH |
| 3 | U.S. Treatment Growth Normalization | Management targets 2%+ once mortality normalizes. Currently ~flat. HDF, antimicrobial catheter solutions, quality initiatives, GLP-1 mortality benefit all support the path. Each 1% treatment growth = meaningful operating leverage. | 2027+ | HIGH |
| 4 | Value-Based Care Inflection | Reached breakeven in 2025 (from EUR -28M in 2024). Over EUR 2B revenue. Low single-digit margin aspiration by 2030. Interwell Health ownership increase strengthens vertical integration. | 2026-2028 | MEDIUM |
| 5 | Share Buyback Program | EUR 1B program (EUR 586M executed in 2025, ~EUR 414M tranche launched Jan 2026). At current prices, retiring ~5% of shares annually. Direct EPS accretion (68% EPS growth in Q4 vs. 53% OI growth). | 2025-2026 | MEDIUM |
| 6 | Revenue Cycle Management | Reduced implicit price concessions driving higher revenue yield per treatment. Structural and sustainable improvement in collections. | Ongoing | MEDIUM |
| 7 | GLP-1 as Volume Positive (Paradox) | GLP-1s slow CKD progression but keep patients alive longer on dialysis. Management calls out "GLP-1 mortality benefit" as supporting 2%+ treatment growth. Patients on GLP-1s may have longer dialysis tenure. | 2027+ | LOW-MED |
| 8 | CMS 2026 Reimbursement Increase | +2.2% ESRD PPS base rate increase to $281.71. Modest but positive and already realized. | 2026 | LOW |
Key risks (bear case)
| # | Risk | Severity | Probability | Detail |
|---|---|---|---|---|
| 1 | TDAPA Phase-Out Headwind | HIGH | NEAR-CERTAIN | EUR 220M phosphate binder benefit in 2025 declining to ~EUR 100M in 2026. EUR 150-200M total regulatory headwind in 2026 (includes ACA). 2027 further erosion as TDAPA products enter bundle -- magnitude unknown. |
| 2 | ACA Subsidy Expiration | MED-HIGH | MED-HIGH | Extended tax subsidies for ACA exchange plans may expire. ~EUR 50M estimated 2026 impact. If subsidies lapse, ~2-5% of patients could shift to less favorable payer mix (Medicaid/uninsured). DaVita has quantified multi-year impact; FMS has not. |
| 3 | GLP-1 Long-Term Demand Destruction | POTENTIALLY HIGH | LOW-MED | Semaglutide approved Jan 2025 for CKD in T2D. FLOW trial: 24% reduction in major kidney events. If GLP-1 adoption reaches scale, fewer patients progress to ESRD/dialysis over 10-15 year horizon. Not a 2026 issue but the key long-tail existential question. |
| 4 | Flat/Negative U.S. Treatment Growth | MEDIUM | MED-HIGH | Guided flat for 2026. Elevated mortality, missed treatments, and weather/flu effects have kept growth near zero for 3 years. Each year of flat growth erodes the "normalization to 2%+" thesis credibility. |
| 5 | 5008X Rollout Execution Risk | MEDIUM | LOW-MED | Training 7,200+ staff, converting 36,000 patients across 28 states in one year. OpEx headwind from training costs (EUR 100-150M strategic investments). If rollout delays, benefits push further right. |
| 6 | China Regulatory / VBP Pressure | LOW-MED | HIGH | ~7-10% of Care Enablement revenue. EUR ~50M EBIT drag in 2025, expected lower in 2026 but ongoing. Volume-based procurement and delayed tenders. |
| 7 | FX Translation Risk | MEDIUM | ONGOING | EUR-reporting company with ~60% USD revenue. Each 1 cent EUR/USD move = ~EUR 20-25M translational OI impact. |
| 8 | Labor Cost Inflation | MEDIUM | HIGH | ~EUR 200-300M assumed inflationary pressure in 2026 (3% net labor + cost inflation). Medical benefit costs for employees were EUR ~80M above plan in 2025 -- unclear if structural. Nursing shortage remains industry headwind. |
| 9 | Tariff Risk on Supply Chain | LOW-MED | MEDIUM | Management flagged tariffs as a 2026 planning variable. Manufacturing in Germany, Mexico, China -- exposure depends on trade policy developments. |
| 10 | Home Dialysis Competitive Threat | LOW | LOW-MED | PD adoption grew from 7.5% to 13.4% of new patients (2011-2021). If home dialysis accelerates, in-center volumes erode. FMS participates in home via products and HDF strengthens in-center value proposition. |
Scenario analysis
| Scenario | 12-Mo Target | Upside/Downside | Key Assumptions |
|---|---|---|---|
| Bull (Score 8-9) | $30-35 | +35-55% | HDF rollout executes flawlessly; treatment growth inflects to 1%+ exiting 2026. FME25+ delivers above EUR 250M. ACA subsidies extended. Multiple re-rates toward DaVita (12x fwd = ~$29). Buyback compresses share count 5%+ annually. VBC delivers low-single-digit margin by 2027. |
| Base (Score 5-6) | $22-26 | Flat to +15% | Treatment growth stays flat in 2026; HDF benefits visible but modest. TDAPA phase-out creates Y/Y earnings pressure; guided flat OI achieved. FME25+ offsets inflation. ACA subsidy partially extended. Stock trades range-bound at 9-10x forward as market waits for 2027 proof points. |
| Bear (Score 2-3) | $16-18 | -20-30% | U.S. treatment volumes turn negative. TDAPA headwind at high end; ACA subsidies fully expire. GLP-1 narrative intensifies, compressing multiple. HDF rollout hits operational snags; benefits delayed to 2028. China deteriorates. Stock de-rates to 7-8x forward = $16-19. |
The base case implies flat-to-modest upside from current levels -- reflecting a 12-18 month dead-money
period before catalysts materialize. The bull case requires HDF execution and multiple re-rating toward
DaVita. The bear case (volume declines + TDAPA + GLP-1 narrative) has a floor around $16-18 where
the dividend yield and buyback provide support. The wide range reflects genuine uncertainty around
regulatory headwinds, treatment growth normalization, and the GLP-1 existential question.
Score rationale
Score of 6/10 reflects moderately favorable risk/reward where the stock is cheap for a reason, but catalysts are credible and management has earned trust through FME25+ execution.
Positives: Valuation cushion at 9.3x forward P/E, 30%+ discount to DaVita, 2.5% yield, and active buyback provide meaningful margin of safety (+1.5). Near-term catalysts in HDF rollout and FME25+ cost savings are real, though benefits are back-loaded to 2027+ (+1.0). Management execution track record is strong -- exceeded FME25+ targets, delivered strong Q4, credible CEO (+0.5). Balance sheet improving with net leverage down to 2.5x from 3.4x, plus EUR 1B buyback program (+0.5).
Negatives: TDAPA/regulatory headwind of EUR 150-200M in 2026 is high-visibility and near-certain, creating tough year-over-year comps (-1.5). Treatment growth stagnation -- 3 years of ~flat U.S. volumes with no clear inflection yet erodes the normalization thesis (-1.0). GLP-1 existential question is long-tail but compresses the multiple (-0.5). 2026 is a transition year with guided flat OI; market needs to wait for 2027+ proof points (-0.5).
The key question is patience: investors must underwrite a 2027+ payoff with limited near-term earnings growth. Suitable for value-oriented investors comfortable with a 12-18 month dead-money period before catalysts materialize.
Analysis as of April 4, 2026. Price: $22.41. Data sourced from Daloopa.